The use of cetuximab for colorectal cancer was highest in france and the united states and lowest in finland 法國及美國應(yīng)用西妥昔單抗治療直腸結(jié)腸癌最多,而芬蘭最低。
Two of the drugs have already been approved for clinical use : cetuximab and celecoxib , while the third , gm6001 , is still experimental 其中兩種藥物已經(jīng)批準(zhǔn)應(yīng)用于臨床:西妥昔單抗和塞來考昔,另一種加貝酯則仍在實(shí)驗(yàn)中。
The largest disparities were in the use of the new colorectal and lung cancer drugs : bevacizumab , cetuximab , erlotinib and pemetrexed , the study found 差別最為懸殊的是新型抗結(jié)腸直腸癌及肺癌藥物的應(yīng)用,這些藥物包括貝伐單抗、西妥昔單抗、埃羅替尼及培美曲塞。
Purpose : this phase ii trial is studying how well giving oxaliplatin and capecitabine together with cetuximab works in treating patients with advanced liver cancer and liver dysfunction 目的:本ii期臨床試驗(yàn)是研究如何聯(lián)合應(yīng)用奧沙利鉑和卡培他來治療晚期肝癌和肝功能障礙。
Conclusion : these results confirm the high prognostic value of kras mutations on response to cetuximab and survival in metastatic crc patients treated with cetuximab 結(jié)論:這些結(jié)果證實(shí)了: kras突變對于轉(zhuǎn)移性crc患者使用西妥昔單抗治療時對西妥昔單抗耐藥情況和生存期具有很高的預(yù)測價值。